Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC) (LOGIC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00571272|
Recruitment Status : Recruiting
First Posted : December 11, 2007
Last Update Posted : March 31, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease|
|Liver Diseases Alagille Syndrome Alpha 1-Antitrypsin Deficiency|
Cholestasis is a rare condition that involves a reduction or obstruction of bile flow from the liver to the small intestine. When bile flow is hindered, a waste product pigment called bilirubin can escape into the bloodstream and build up to harmful levels. This may lead to the easily recognizable cholestatic symptoms of jaundice, itching, and impaired growth and eventually to more serious health problems. Four rare genetic liver disorders- ALGS, a-1AT, bile acid synthesis and metabolism defects, and PFIC-account for about 20% to 30% of all infant cases of cholestasis. These four disorders compose a group of related diseases that can cause significant growth problems during childhood, serious liver problems, the need for liver transplantation, and potentially death. More research on these rare liver diseases is necessary to develop a scientific basis for improvement in diagnostic techniques and treatments. Current diagnostic procedures are complex, and the development of simpler diagnostic tests would facilitate early diagnosis and treatment. This study will investigate the natural history and progression of the four previously mentioned cholestatic liver diseases to provide a better understanding of the causes and effects of the diseases.
Participation in this study will last 20 years and will consist of a baseline visit and 20 annual follow-up visits. The study will enroll infants through adults 25 years of age who have, or are suspected of having, one of the four genetic cholestatic liver diseases. Individuals who are siblings of a-A1T participants and have underlying disease with no evidence of liver involvement may also be enrolled. Study visits will involve review of clinical information, family history, and any clinically indicated treatments and their outcomes; a physical exam; laboratory tests; and radiologic and imaging evaluations. In addition to these standard of care evaluations, participants will undergo several special research evaluations, including quality of life questionnaires, neurodevelopmental evaluations, hearing exams, liver histology studies, and collection of serum, plasma, urine, and blood for DNA. Serum, plasma, and blood for DNA will also be collected from both biological parents and from affected siblings of participants with a-A1T or ALGS. Genetic testing will be performed using the collected specimens.
|Study Type :||Observational|
|Estimated Enrollment :||1675 participants|
|Official Title:||Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)|
|Actual Study Start Date :||November 30, 2007|
|Estimated Primary Completion Date :||May 2024|
|Estimated Study Completion Date :||May 2024|
Infants less than 6 months old with a cholestatic liver disease who were initially enrolled into the Childhood Liver Disease Research and Education Network (ChiLDREN) Prospective Biliary Atresia Epidemiology study (PROBE study; P003)
Participants with a cholestatic liver disease who are between birth and 25 years old who were NOT initially enrolled into the Childhood Liver Disease Research and Education Network (ChiLDREN) Prospective Biliary Atresia Epidemiology study (PROBE study; P003)
Post-liver transplant participants with a cholestatic liver disease who are between 1 day and 25 years old. Affected parents of patients enrolled in the study are eligible for enrollment if they are 25 years old or less
A screening group of participants, birth through 25 years old, suspected of having ALGS, PFIC (or BRIC) or BAD, who do not meet complete enrollment criteria for Group 1, 2, or 3.BRIC)
Affected siblings (without evidence of liver disease) of Alpha-1 Antitrypsin Deficiency participants who are enrolled in LOGIC.
- Demonstration of disease progression for each of the four cholestatic liver diseases of the study, including liver transplantation, death, growth failure, worsening liver function, and developmental complications of portal high blood pressure [ Time Frame: Measured at baseline and annually through year 10 ]
- Jaundice (total serum bilirubin of greater than 2.0 mg/dl) [ Time Frame: Measured at baseline and annually through year 10 ]
- Listing for liver transplantation [ Time Frame: Measured at baseline and annually through year 10 ]
- Calculated Pediatric End-Stage Liver Disease (PELD) score for participants less than 12 years of age or Model for End-Stage Liver Disease (MELD) score for participants 12 years of age or older [ Time Frame: Measured at baseline and annually through year 10 ]
- Health related quality of life [ Time Frame: Measured at baseline and annually through year 10 ]
- Growth (length and weight Z-score) [ Time Frame: Measured at baseline and annually through year 10 ]
- Bone mineral density (lumbar and spine total body) [ Time Frame: Measured at baseline in ALGS and PFIC/BRIC subjects ]
- Presence of hearing loss (ALGS and PFIC) [ Time Frame: Measured at baseline ]
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||up to 25 Years (Child, Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
- Children and young adults diagnosed with one of the four cholestatic diseases from birth through 25 years old.
- Siblings of participants with alpha-1-antitrypsin deficiency, who themselves have alpha-1-antitrypsin deficiency of liver disease.
- Both genders, all races and ethnic groups
- Participant meets the enrollment criteria for one of the four cholestatic liver diseases
- Inability to comply with the longitudinal follow-up described below, or
- Failure of a family/patient to sign the informed consent document or the HIPAA medical record release form.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00571272
|Contact: Terese A Howell, BS, CCRCemail@example.com|
|Contact: Sayori Suda-Wilson, BS, RDfirstname.lastname@example.org|
|Study Chair:||Kathleen Loomes, MD||Children's Hospital of Philadelphia|
|Study Director:||Ed Doo, MD||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|
|Principal Investigator:||John Magee, MD||University of Michigan|
|Principal Investigator:||Robert Merion, MD||Arbor Research Collaborative for Health|
|Study Director:||Averell Sherker, MD||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Cholestatic Liver Disease
Bile Acid Synthesis and Metabolism Defects
Progressive Familial Intrahepatic Cholestasis
Alpha 1-Antitrypsin Deficiency
Digestive System Diseases
Bile Duct Diseases
Biliary Tract Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Heart Defects, Congenital